admin_it9vh6y7

AI-discovered candidate CHM-029 demonstrates robust, dose-dependent tumor regression in pre-clinical AML models and retains potency against all known resistance mutations First-in-human trials expected to begin in Q2 2026 LONDON – 13 November 2025 — CHARM Therapeutics (“CHARM”, “The Company”), today…

LONDON – 8 September 2025 — CHARM Therapeutics (“CHARM”, “The Company”), announces the appointment of Dr Erkut Bahceci as Chief Medical Officer. Erkut’s appointment follows CHARM’s $80 million Series B financing, co-led by NEA and SR One, to advance its…

New investors NEA and SR One lead round alongside existing investors OrbiMed, F-Prime, NVIDIA and Khosla Ventures CHARM’s AI-designed menin inhibitor overcomes resistance mutations with the potential to deliver superior efficacy, durability and safety; clinical development expected to start 1Q26…